VivoSim’s AI-Enabled Models Outperform Competitors in Liver Toxicity Prediction
Event summary
- VivoSim presented data at the European Toxicology Meeting showing its AI-enabled models achieve >90% sensitivity in liver toxicity prediction, outperforming traditional methods (50-65%).
- The company’s NAMkind™ Liver and GI platforms demonstrated <5% false positives compared to >10% in current methodologies.
- VivoSim’s models successfully predicted clinical profiles for Antibody Drug Conjugates (ADCs), a fast-growing oncology modality.
- Presentations highlighted the ability to differentiate ADC risk based on structural properties, including linker stability and payload permeability.
The big picture
VivoSim’s superior predictive accuracy aligns with the FDA’s shift away from animal testing, positioning it as a key player in preclinical safety evaluation. The company’s ability to predict liver and gastrointestinal toxicity across both small molecules and complex ADCs addresses a critical gap in drug development, potentially saving pharma companies millions in failed trials.
What we're watching
- Regulatory Tailwinds
- How the FDA’s push for human-relevant NAMs will accelerate VivoSim’s adoption among pharma clients.
- Market Expansion
- Whether VivoSim can sustain its competitive edge as it expands into new biotech modalities like ADCs and gene therapies.
- Execution Risk
- The pace at which VivoSim can scale its capacity to meet growing global demand for in vitro toxicology testing.
Related topics